Skip to main content

Table 1 Baseline clinical features of ALS patients for group A and group B

From: A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis

Clinical features All patients (50)–T0 Analyzed patients (43)–T0 All patients (39)–T1 Analyzed patients (27)–T1 All patients (31)–T2 Analyzed patients (20)–T2
Group A Group B Group A Group B Group A Group B Group A Group B Group A Group B Group A Group B
Number (sex, male) 25 (M 15) 22 (M 14) 22 (M 12) 21 (M 12) 19 (M 10) 20 (M 12) 13 (M 7) 14 (M 8) 15 (M 9) 16 (M 10) 10 (M 7) 10 (M 6)
Age (SD) 60.36 (10.86) 59.64 (8.12) 59.64 (8.12) 59.71 (10.03) 62.0 (11.15) 57.95 (11.25) 59.77 (10.05) 60.71 (10.09) 61.2 (11.47) 57.56 (11.58) 58.9 (10.88) 62.4 (11.80)
BMI (SD) 24.82 (3.95) 24.84 (3.97) 24.84 (3.97) 22.84 (4.01) 24.70 (4.03) 23.28 (4.18) 25.65 (4.39) 23.19 (4.44) 24.21 (3.86) 23.09 (3.96) 24.64 (4.19) 23.17 (4.53)
Spinal onset (n, %) 20 (80%) 18 (82%) 18 (82%) 17 (81%) 16 (84%) 17 (85%) 12 (92%) 12 (86%) 12 (80%) 14 (88%) 9 (90%) 10 (100%)
Disease duration (SD) 20.91 (10.89) 19.85 (10.71) 21.54 (10.90) 19.14 (10.70) 22.47 (9.70) 23.65 (9.98) 24.23 (9.16) 22.71 (9.60) 27.07 (9.65) 27.56 (10.14) 29.9 (9.26) 25.50 (9.28)
FVC% (SD) 81.48 (18.28) 83.90 (18.46) 83.90 (18.46) 85.52 (18.79) 72.26 (22.0) 74.22 (21.35) 80.0 (19.27) 78.67 (17.78) 64.71 (24.9) 74.57 (23.99) 68.67 (22.38) 81.0 (22.39)
ALSFRS-R (SD) 36.56 (5.82) 36.77 (5.88) 36.77 (5.88) 36.05 (5.86) 36.26 (7.55) 31.77 (7.26) 36.85 (7.55) 31.28 (7.02) 33.64 (9.24) 31.0 (9.10) 33.22 (7.99) 31.11 (8.33)
Bulbar ALSFRS-R (SD) 11.26 (1.53) 11.35 (1.52) 10.47 (1.49) 10.29 (1.52) 11.2 (1.73) 11.36 (1.23) 10.33 (1.54) 10.15 (1.72) 9.6 (2.42) 10.43 (1.98) 9.92 (2.36) 9.87 (1.97)
Delta ALSFRS-R (SD) 0.63 (1.36) 1.08 (1.43) 0.77 (1.38) 1.45 (1.55) 0.93 (1.05) 0.8 (0.99) 1.0 (0.88) 0.63 (0.77)
  1. The values are expressed as mean (SD). BMI body mass index, FVC forced vital capacity, ALSFRS-R ALS Functional Rating Scale–Revised. P value: not statistically significant for each analysis (> 0.05). T0: baseline, T1: 3 months since treatment start, T2: 6 months since treatment start. The value of disease duration is in months. Delta ALSFRS-R is calculated as monthly progression